References
- de Jong MH, Zemel D, Van Gool AR. Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease. Clin Schizophr Relat Psychoses 2014;8:36-40. https://doi.org/10.3371/CSRP.DEZE.012513
- Friedman JH, Fernandez HH. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease. Clin Neuropharmacol 2001;24:120-121. https://doi.org/10.1097/00002826-200103000-00012
- Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014;5:47.
- Lim TT, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, et al. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease? Int J Neurosci 2013;123:170-174. https://doi.org/10.3109/00207454.2012.732976
- Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014;20:808-814. https://doi.org/10.1016/j.parkreldis.2014.05.011
- Freidman JH, Factor SA. Atypical antipsychotics in the treatement of drug-induced psychosis in Parkinson's disease. Mov Discord 2000;15:201-211. https://doi.org/10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D
- Im JH, Kang JH, Lee MC. Treatment of Parkinson's disease. J Korean Neuroll Assoc 2001;19:315-336.